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Endometrial cancer is the most common gynecologic malignancy in developed countries.
Its increasing incidence is thought to be related in part to the rise of metabolic
syndrome, which has been shown to be a risk factor for the development of
hyperestrogenic and hyperinsulinemic states. This has consequently lead to an increase
in other hormone-responsive cancers as well e.g., breast and ovarian cancer. The
correlation between obesity, hyperglycemia, and endometrial cancer has highlighted the
important role of metabolism in cancer establishment and persistence. Tumor-mediated
reprogramming of the microenvironment and macroenvironment can range from
induction of cytokines and growth factors to stimulation of surrounding stromal cells
to produce energy-rich catabolites, fueling the growth, and survival of cancer cells.
Such mechanisms raise the prospect of the metabolic microenvironment itself as a
viable target for treatment of malignancies. Metformin is a biguanide drug that is a
first-line treatment for type 2 diabetes that has beneficial effects on various markers
of the metabolic syndrome. Many studies suggest that metformin shows potential as
an adjuvant treatment for uterine and other cancers. Here, we review the evidence for
metformin as a treatment for cancers of the endometrium. We discuss the available
clinical data and the molecular mechanisms by which it may exert its effects, with a focus
on how it may alter the tumor microenvironment. The pleiotropic effects of metformin
on cellular energy production and usage as well as intercellular and hormone-based
interactions make it a promising candidate for reprogramming of the cancer ecosystem.
This, along with other treatments aimed at targeting tumor metabolic pathways, may lead
to novel treatment strategies for endometrial cancer.
Keywords: tumor microenvironment, metabolism, metformin, endometrial cancer, reverse Warburg

ENDOMETRIAL CANCER
Cancer of the endometrium is the fifth most common malignancy in women worldwide, with
455,000 new cases diagnosed worldwide in 2015 (1). The incidence is rising, and is noted to
be much higher in developed than developing countries (1, 2). The American Cancer Society
estimates that 63,230 new cases will be diagnosed in the United States in 2018 (representing 7%
of cancer diagnoses in women), with 11,350 predicted deaths (3). The majority of cases arise
in the post-menopausal period, but up to 14% of cases occur in women age 40 or younger (4).
The principal risk factor for development of endometrial cancer is exposure to endogenous and
exogenous estrogens, which is influenced by factors such as age at menarche and menopause, parity,
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(11). The results of single-agent mTOR inhibitor treatment,
or EGFR and HER2 inhibitors have been disappointing,
with response rates of 0–12%. Anti-angiogenic drugs such as
bevacizumab, sunitinib, brivanib, and lenvatinib have resulted
in slightly higher objective response rates of 14–19%. Studies
of additional targets, including fibroblast growth factor receptor
(FGFR), luteinizing hormone releasing hormone (LHRH), poly
ADP-ribose polymerase (PARP), and Programmed Death1/Programmed Death Ligand-1 (PD-1/PD-L1) are underway. At
this point, no targeted therapies have been approved. Therefore,
further interest has been focused on other factors that could
contribute to development and progression of endometrial
cancer.

use of unopposed estrogen therapy or other hormonal therapies
(e.g., tamoxifen), and a host of metabolic factors including
obesity. 5–25% of cases are also associated with high risk germline
mutations, particularly those affecting DNA mismatch repair
pathways, leading to early onset of disease (5).
The most common classification system divides endometrial
cancers into two subtypes (6). Type I cancers are lowgrade, diploid, endometrioid, and hormone-receptor positive,
carrying a better prognosis. They frequently display mutations in
phosphate and tensin homolog (PTEN). Type II cancers (which
include the serous, clear cell, mixed cell, undifferentiated, and
carcinosarcoma histologies) are high grade, non-endometrioid,
aneuploid, and hormone-negative, with higher rates of metastasis
and worse prognosis. They tend to occur in older patients and
are more likely to have mutations in the tumor suppressor p53.
Type II cancers make up only 10% of endometrial cancers but
account for almost 50% of relapses and deaths (7), suggesting a
fundamental biologic difference between the two subsets.
Most cases are diagnosed at an early stage due to the early
detection sign of abnormal bleeding. Standard treatment for
apparent stage I endometrial cancer consists of surgical resection
(primary hysterectomy with bilateral salpingo-oophorectomy
with possible lymph node mapping). Disease that is confirmed
to be uterine-confined with low risk features, can be treated
with surgery only and has a >90% relapse-free survival rate
at 5 years (8). Radiation decreases local relapse rates but
does not affect relapse at distant sites or increase overall
survival (9, 10). Trials of adjuvant chemotherapy alone with
cyclophosphamide, doxorubicin, and cisplatin demonstrated no
significant improvement in progression-free survival, overall
survival, or relapse (11). Combined adjuvant chemoradiation
has shown a slight increase in progression-free survival but not
overall survival (11).
For metastatic or recurrent disease, management may include
surgery or radiation (if localized to a single site); those
with unresectable disease may sometimes receive primary
chemotherapy followed by cytoreductive surgery. For disease not
amenable to local therapy, a carboplatin-paclitaxel combination
is increasingly used as a first-line alternative to the traditional
cisplatin, paclitaxel, and doxorubicin (7). With respect to
hormonal therapy in advanced disease, a 33% response rate was
noted after alternating tamoxifen and medroxyprogesterone (11–
13). In recurrent or metastatic disease, progestogens, tamoxifen
alternated with megestrol, gonadotropin-releasing hormone
analogues, selective estrogen receptor modulators, and aromatase
inhibitors have been used with response rates ranging from 11
to 56% (13, 14). Ultimately, the response rates for recurrent
advanced disease are low, and there are no standard second line
therapies (13, 15).
This lack of effective treatment for advanced stage endometrial
cancer has led to exploration of alternative therapeutic
modalities. In particular, numerous studies have examined the
effectiveness of targeted therapies acting on the phosphoinositide
3-Kinase (PI3K)/Protein kinase B (Akt)/mammalian target of
rapamycin (mTOR) pathway, epidermal growth factor receptor
(EGFR), human epidermal growth factor receptor 2 (HER2), and
vascular endothelial growth factor (VEGF), reviewed elsewhere
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ASSOCIATIONS WITH METABOLIC
SYNDROME, OBESITY, AND METABOLISM
Among the risk factors associated with endometrial cancer,
metabolic syndrome (a constellation of obesity, hyperglycemia,
hypertension, and hyperlipidemia) has attracted a large amount
of interest in recent years. Multiple associative studies have
suggested that the metabolic syndrome is a risk factor for
development of many different types of cancers (16–18),
including endometrial cancer (19–24). A meta-analysis of 6
studies from North America, Europe, and China estimated a
relative risk (RR) for endometrial cancer of 1.89 in patients with
metabolic syndrome (95% confidence interval [CI] 1.34–2.67,
p = 0.001) (25). Another meta-analysis of 7 European cohorts
reported a 56% increase in endometrial cancer risk per increase
of one standard deviation in a composite metabolic risk score
derived from sex- and cohort-specific means in body mass index
(BMI), blood pressure, plasma cholesterol, triglycerides, and
glucose (18). Apart from incidence, Ni and colleagues reported
increased endometrial cancer stage, grade, vascular invasion,
tumor size, and lymphatic metastasis in patients with metabolic
syndrome, as well as decreased overall survival (26).
The individual components of the metabolic syndrome have
also been studied in relation to endometrial cancer risk, but it
is unknown if their contribution is additive or synergistic. In
particular, obesity has been noted to be strongly associated with
risk of endometrial cancer in several case-control studies and
meta-analyses (21–25, 27, 28). Multiple measures of adiposity,
including BMI, waist circumference, waist-to-hip-ratio, and hip
circumference, have been found to be directly associated with
endometrial cancer incidence. Increased waist circumference
and BMI have also been shown to be significantly associated
with increased risk of overall mortality from endometrial cancer
(29, 30). Other studies have demonstrated positive albeit less
robust association between endometrial cancer and the other
components of the metabolic syndrome: hypertension (21–24),
hyperlipidemia (21–24), and hyperglycemia or diabetes mellitus
(19, 21–25, 31, 32). The association between diabetes and
endometrial cancer appears to be partially confounded by coexisting overweight/obesity (33, 34). However, elevated risk of
endometrial cancer in patients with diabetes has been reported
even after adjustment for BMI, with one meta-analysis including
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overall cancer incidence in metformin users, reviewed by several
groups (47–53). Studies evaluating the relationship between
metformin use and endometrial cancer incidence specifically
have yielded more conflicting results. Three cohort studies
and two case-control studies found no decrease in the risk of
endometrial cancer in metformin users compared to nonusers
(34, 42, 43, 45, 46). However, these studies show considerable
heterogeneity in factors such as study size, indication for
metformin use, and duration and method of measurement of
metformin exposure (e.g., prescriptions vs. self-report). Notably,
a large study of 478,921 Taiwanese women with diabetes showed
a significantly decreased incidence of endometrial cancer (hazard
ratio [HR] 0.675, 95% CI 0.614–0.742) in metformin users
compared to never users (44). When stratified by duration of
use or cumulative doses, the decrease in incidence demonstrated
a dose-response effect. Additionally, a meta-analysis by Tang
and colleagues found that metformin use was associated with a
decreased risk of endometrial cancer incidence (RR 0.87, 95% CI
0.80–0.95) (54).
Other associative studies have focused instead on the
relationship between metformin exposure and endometrial
cancer outcomes (Table 2). Metformin use in diabetic patients
with endometrial cancer was associated with improved overall
survival compared to those not taking metformin in two separate
studies, including one involving patients with stage III–IV or
recurrent endometrial cancer receiving chemotherapy (56, 59).
The study by Ko also found improved recurrence-free survival
in patients taking metformin. In contrast, some did not find any
effect of metformin exposure on survival parameters (57, 58, 61).
Still others have reported effects only on certain subgroups of
patients. For example, Nevadunsky found increased survival for
metformin users only among patients with non-endometrioid
but not endometrioid forms of endometrial cancer (55), while
Hall reported a significantly lower recurrence rate of only
endometrioid endometrial cancers among metformin users (60).
As with the incidence research, these studies are limited by
heterogeneity and sample size. However, a 2017 meta-analysis
including 6 of the above studies supports a higher overall survival
rate in metformin-users with endometrial cancer compared
to non-metformin users and non-diabetic patients (HR 0.82,
95% CI 0.70–0.95, I 2 = 40%) (62). Finally, a meta-analysis of
28 studies reported that metformin use was associated with
decreased all-cause mortality in patients with concurrent diabetes
for several cancer types, including endometrial (RR 0.49, 95% CI
0.32, 0.73, p < 0.001) (63).

29 cohort studies reporting a summary relative risk of 1.89 [95%
CI, 1.46–2.45, p < 0.001] (32). This study also noted a small
increased risk of disease-specific mortality in diabetic patients
with endometrial cancer (RR 1.32, 95% CI, 1.10–1.60; p = 0.003).
The major driver of increased risk of endometrial and other
hormone-responsive cancers in obesity is thought to be the
generation of a hyper-estrogenic state caused by the presence
of the aromatase enzyme in adipose tissue (35). This enzyme
catalyzes conversion of androgens to estrogens, making adipose
tissue a key source of estrogens in post-menopausal women.
In addition, adiposity has been associated with other factors
that may drive tumorigenesis in general, including increased
inflammation, depressed immune function, and chronic insulin
resistance and hyperinsulinemia. Endometrial cancer patients
have been shown to have increased markers of insulin resistance,
including higher fasting insulin levels and elevated non-fasting
and fasting C-peptide levels (36, 37). Supporting this link
between abnormal glucose metabolism and cancer risk is the
observation that better diabetic control is associated with
decreased endometrial cancer risk (21). Ultimately, these data
suggest that abnormal metabolism, including insulin resistance
and hyperglycemia, may play a role in the development of
endometrial cancer and thus represent a possible therapeutic
target.

METFORMIN REPURPOSING AND
EPIDEMIOLOGIC DATA FROM
ENDOMETRIAL CANCER
In recent years there has been growing interest in drug
repurposing or repositioning, a process which seeks to identify
new pharmacologic properties (e.g., anti-tumorigenic) of existing
medications for use as primary or adjuvant treatments for other
conditions (38, 39). These drugs are already well-studied in terms
of tolerability and side effects, often inexpensive, and amenable
to retrospective and associative studies as many patients are
already taking them for other indications. The association
between obesity, diabetes, hyperinsulinemia, and endometrial
cancer has led to the hypothesis that medications which target
glucose metabolism such as metformin may be effective in
preventing or treating such malignancies. One drug that has
received a significant amount of attention in this arena has
been metformin [1,1-dimethylbiguanide] which is a first line oral
antihyperglycemic agent used in the treatment of type 2 diabetes
(40). Broadly, its effects include lowering of blood glucose
concentrations, increasing insulin sensitization, and reducing
plasma fasting insulin levels. Furthermore, unlike with some
oral hypoglycemic medications and insulin, metformin users
show a tendency toward sustained weight loss (41). The low
toxicity of metformin makes it especially interesting as a potential
adjunctive therapy, or even as monotherapy for patients with
contraindications to chemotherapy or considerations such as the
desire to preserve fertility.
Many investigators have sought to examine the effect of
metformin exposure on the development of endometrial cancer
(Table 1). Multiple epidemiologic studies have reported lower
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CELLULAR AND MOLECULAR
MECHANISMS OF METFORMIN
INHIBITION OF ENDOMETRIAL CANCER
Metabolic alterations in endometrial cancer have been described
not only on a systemic but also on a cellular and molecular
level. For example, Byrne and colleagues examined microarray
data from women with women with type I endometrial cancer
and demonstrated that tumor-derived endometrium showed
enrichment of genes related to glycolysis and lipogenesis
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low, normal, or high glucose conditions (65). High glucose
conditions (corresponding to physiologic hyperglycemia) led
to increased cell proliferation, in vitro colony formation, and
increased expression of the GLUT1 glucose transporter along
with increased glucose uptake. High glucose also increased
phosphorylation of lactate dehydrogenase A (LDHA) and
decreased levels of pyruvate dehydrogenase (PDH), suggesting an
increase in glycolytic activity. Conversely, low glucose conditions
led to increased cell apoptosis, cell cycle arrest, decreased
adhesion, and invasion. All of these data support the idea that
the metabolic vulnerabilities of endometrial cancer may make it
susceptible to therapies such as metformin.
Multiple studies have demonstrated the ability of metformin
to inhibit proliferation of both type I and type II human
endometrial cancer cell lines in culture (66–73). Metformin
treatment of endometrial cancer cell lines upregulates markers
of cell cycle arrest (66, 68, 69, 74), apoptosis (66, 67, 69, 72,
73, 75, 76), and autophagy (69, 77), while decreasing markers
associated with senescence (66, 74) and inhibiting cell migration
(68, 71, 76). The anticancer effects of metformin treatment may
not be limited to direct effects on endometrial cancer cells, but
may also result from changes to the systemic milieu. Polycystic
ovary syndrome (PCOS) is a condition which is associated
with endometrial hyperplasia and predisposition to endometrial
cancer (78). Endometrial cancer cell lines incubated with sera
from PCOS patients showed increased migration and markers
of invasiveness such as activity of matrix metalloproteinases
(MMP)−2 and −9 compared to cells incubated with sera from
healthy controls. In contrast, sera from PCOS patients treated
with metformin for 6 months showed attenuation of this effect,
with decreased migration and MMP-2/9 activity compared to
cells treated with sera from PCOS patients not on metformin
(79).
The molecular mechanisms of metformin’s effects in
endometrial cancer cells are diverse and continue to be an
active area of investigation (Figure 1). Its general mechanisms
are complex and multifactorial and are reviewed in detail
elsewhere (80). Multiple groups have demonstrated that
metformin’s ability to inhibit oxidative phosphorylation
(OXPHOS) at the mitochondrial level is an important mediator
of its biologic activity (81, 82). The end result is a decrease in
proton gradient across the inner mitochondrial membrane,
ultimately leading to reduction in proton-driven synthesis of
adenosine triphosphate (ATP) and an increase in the ratio of
cellular adenosine monophosphate (AMP) to ATP, caused by
imbalance in the rate of ATP production vs. consumption.
The decrease in ATP is theorized to be responsible for a key
effect of metformin treatment, namely, phosphorylation and
activation of the serine/threonine AMP-activated protein
kinase (AMPK), a regulatory protein which plays a role in
sensing and energy status of the cell and regulating cellular
function under conditions of energy restriction (83, 84). This
leads to AMP binding to AMPK and a conformational change
that allows for phosphorylation/activation of AMPK by liver
kinase B1 (LKB1) (85). Activation of AMPK switches cells to
a catabolic state via AMPK-mediated phosphorylation and
inhibition of key enzymes and transcription factors involved

TABLE 1 | Studies of metformin use and incidence of endometrial cancer.
References Design

Results

(42) (UK)

Case-control 2,554 cases,
15,324 controls

• Ever-use of metformin not
associated
with
risk
of
endometrial
cancer
(OR
0.86, 95% CI 0.63–1.18)
• Long-term use of metformin
(>25 prescriptions) not
associated with risk of
endometrial cancer (OR 0.79,
95% CI 0.54–1.17)

(34) (USA)

Retrospective cohort 88,107
postmenopausal women (age
50–79)

• Self-reported metformin use at
study baseline not associated
with risk of endometrial cancer
(HR 1.64, 95% CI 0.92–2.91)

(43) (USA)

Retrospective cohort 541,128
women (new prescription of
metformin or sulfonylurea, any
indication)

• Metformin use not associated
with endometrial cancer risk
compared to sulfonylurea use
(HR 1.09, 95% CI 0.88–1.35)

(44)
(Taiwan)

Retrospective cohort 478,921
women (new diagnosis of type 2
diabetes)

• Ever-use
of
metformin
associated with decreased
incidence
of
endometrial
cancer (HR 0.675, 95% CI
0.614–0.742)
• Dose-response was observed
when adjusted for duration of
metformin use or cumulative
metformin doses

(45) (Italy)

Case-control 376 cases, 7,485
controls

• Ever-use of metformin use not
associated with endometrial
cancer risk (OR 1.07, 95% CI
0.82–1.41)

(46)
(Finland)

Retrospective cohort 92,366
women (new diagnosis of type 2
diabetes) Nested case-control
590 cases (endometrioid),
11,792 controls

• Metformin ever-use associated
with
increased
risk
of
endometrial cancer in full
cohort (OR 1.23, 95% CI
1.03–1.48).
• Metformin use associated with
increased risk of endometrial
cancer in nested case-control
(OR 1.24, 95% CI 1.02–1.51)

OR, odds ratio; CI, confidence interval; HR, hazard ratio.

compared to normal endometrium (64). They also reported
that multiple human endometrial cancer cell lines showed
strong upregulation of the glucose transporter GLUT6 as
well as activation of AKT compared to nonmalignant cells.
In vitro metabolic profiling demonstrated that these changes were
associated with upregulation of glycolysis, decreased glucose
oxidation, and increased de novo lipogenesis. Finally, the authors
demonstrated that endometrial cancer cell cultures experience
cytotoxicity when exposed to a variety of inhibitors targeting
metabolic pathways, including the glycolysis inhibitors 2-deoxyD-glucose [2-DG] and 3-bromopyruvate (BrPA), the lipogenesis
inhibitor 5-(tetradecyloxy)-2-furoic acid (TOFA), the fatty acid
oxidation inhibitor etomixir, and the pleiotropic metabolic
inhibitor metformin. Further support for the importance of
glucose metabolism on endometrial cancer cell growth comes
from Han and colleagues, who studied the growth of two
endometrial cancer cell lines (ECC-1 and Ishikawa cells) under

Frontiers in Oncology | www.frontiersin.org
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TABLE 2 | Observational studies of metformin exposure in endometrial cancer.
Number
DM
References

No DM

Total

MFM

No MFM

No MFM

(55) (USA)

985

114

136

735

• Non-endometrioid endometrioid cancer patients had greater OS in metformin vs. nonmetformin users (HR 0.54, 95% CI 0.30–0.97)
• No association between metformin use and endometrioid endometrial cancer (HR 0.79, 95%
CI 0.31–2.0)

(56) (USA)

1,495

196

167

1,132

• RFS 1.8 times worse in patients not on metformin compared to metformin users (95% CI
1.1–2.9)
• OS 2.3 times worse in patients not on metformin compared to metformin users (95% CI
1.3–4.2)
• TTR not associated with metformin use (HR 1.12, 95% CI 0.6–2.2)

107

30

38

39

(58) (USA)

(57) (Poland)

1,303

116

161

1,026

(59) (USA)

349

31

27

291

(60) (USA)

351

64

(61) (Austria)

465

46

287

41

Results

• No difference in OS between metformin users vs. non-users (p = 0.86)
• OS not significantly different between diabetic metformin-users and diabetic non-metformin
users (HR 0.61; 95% CI 0.30–1.23) or non-diabetic patients (HR 1.03; 95% CI 0.57–1.85).
• PFS not significantly different between diabetic metformin-users compared to diabetic
non-metformin users (HR 1.06; 95% CI 0.34–3.30) or non-diabetic patients (HR 1.14; 95%
CI 0.46–2.62)
• OS greater in diabetic metformin-users compared to diabetic patients not taking metformin
(HR 0.42, 95% CI 0.23–0.78) but not compared to non-diabetic patients (HR 0.65, 95% CI
0.41–1.05)
• Recurrence rate for all metformin-users vs. non-metformin users not statistically different, but
recurrence of type I endometrial cancers was significantly lower for metformin users (1.9%)
compared to non-metformin users (10.3%), p = 0.05

378

• Metformin use not associated with OS (HR 0.9, 95% CI 0.69–1.2) or RFS (HR 1.2, 95% CI
0.8–1.70)

MFM, metformin; OS, overall survival; HR, hazard ratio; CI, confidence interval; RFS, recurrence-free survival; TTR, time to regression; PFS, progression-free survival.

mitogen-activated protein-kinase/extracellular signal-regulated
kinase (MAPK/ERK) pathways (92–94). Inhibition of PI3K/Akt
signaling has been observed in metformin-treated endometrial
cancer cells (70), and both Akt and ERK1/2 are inhibited in
endometrial cancer cells incubated with serum from women
with PCOS who are receiving metformin treatment (79). The
cumulative result is inhibition of individual cell growth and
proliferation, decreased synthesis of proteins and fatty acids,
as well as decreased paracrine and endocrine release of proproliferative systemic factors.
In addition to IGF-1-related signaling pathways, metformin
treatment of endometrial cancer cells has been reported to affect
the activity of the transcription factor signal transducer and
activator of transcription 3 (STAT3), which is usually activated
via signaling by various growth factors and cytokines to dimerize,
translocate to the nucleus, and induce transcription of multiple
pro-survival and pro-proliferative genes (95). STAT3 levels are
elevated in endometrial cancer cells, in particular the serinephosphorylated form, phospho-STAT3 Ser727 (96). High glucose
concentrations induces transcription of STAT3 as well as its
upstream regulators Janus kinases 1 and 2 (JAK1/2), while
metformin treatment reduces total STAT3 protein as well as
phospho-STAT3 Ser727 (73). This is associated with significantly
decreased expression of multiple pro-survival downstream
targets of STAT3, including c-Myc and B-cell lymphoma (Bcl)-2
and –XL, providing another possible mechanism for metformin’s
anti-cancer activity. The authors also examined the effect of

in ATP-consuming synthetic pathways (e.g., glucose, lipid and
protein).
Among the known downstream effects of AMPK activation
is decreased protein synthesis due to inhibition of the mTOR
pathway, resulting in the inhibition of translation by the
eukaryotic initiation factor 4E-binding protein-1 [4E-BP1]
complex and decreased activity of the S6 kinase 1 (S6K1)
responsible for phosphorylation of the ribosomal S6 protein
(rpS6) (86, 87). Metformin inhibition of mTOR signaling
in endometrial cancer cells has been confirmed by multiple
groups (66, 74, 88–90). Other well-described effects of AMPK
activation include phosphorylation and inactivation of AcetylCoA carboxylase (ACC) leading to downregulation of fatty
acid synthesis (83, 91) as well as inhibition of signaling via
the insulin-like growth factor-1 receptor (IGF-1R). Metformin
inhibition of ACC has not been reported in endometrial cancer
cell lines, but Wallbillich did observe decreased expression
of fatty acid synthetase (FAS) in metformin-treated tumor
tissue from a xenograft model (73). In endometrial cancer cell
cultures, metformin treatment lowers secretion of insulin-like
growth factor (IGF-1) (70), downregulates expression of insulin
receptor (68) and IGF-1R (70, 75), inhibits phosphorylation
of IGF-1R (68), and increases expression of insulin-like
growth factor-binding protein 1 (IGFBP-1) (75). In other
cancer types, this is associated with inhibitory phosphorylation
of the signaling adapter, insulin receptor substrate-1 (IRS1) and inhibition of the downstream PI3K/Akt/mTOR and
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FIGURE 1 | (A) Mechanisms of action of metformin within the endometrial cancer cell. (B) Downstream molecular targets of metformin showing differential
expression or activity in endometrial cancer.

FOXO1 is negatively regulated via inhibitory phosphorylation
by Akt, which causes it to translocate out of the nucleus to
the cytoplasm where it is degraded (98). Conversely, AMPK
activation leads to FOXO1 nuclear localization and activation
(99). Zou demonstrated that endometrial cancer cells show
decreased levels of phospho-AMPK and total FOXO1 protein,
and endometrial cancer tissues show significantly less staining of
activated AMPK and higher levels of phospho-Akt compared to
controls (72). This is associated with a shift toward cytoplasmic
(inactive) rather than nuclear (active) FOXO1 staining. In vitro,

metformin in a xenograft model of endometrioid endometrial
cancer cells. While not statistically significant, metformin
exposure was associated with a trend toward decreased tumor
size, and analysis of tumor tissues demonstrated decreased
expression of STAT3 and its targets (73).
Another recently-reported target of metformin in endometrial
cancer is the transcription factor forkhead box protein 1
(FOXO1), which plays numerous roles in cellular function,
including regulation of gluconeogenesis, adipogenesis,
protection from oxidative stress, and tumor suppression (97).
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patient biopsies for culture and inoculation into nude mice.
The authors noted that one sample contained a K-Ras mutation
while the other was wild-type; neither tumor was inhibited
by metformin treatment, either alone or in combination with
cisplatin (104). It should be noted that the dosage of metformin
used in this study was lower than in the study by Iglesias (250
mg/kg/day for 21 days vs. 1 g/kg/day for 29-64 days). However,
in both these studies, the tumors that displayed no susceptibility
to metformin treatment also showed no changes in levels of
activated AMPK or downstream mediators, emphasizing the
likely importance of this pathway for mediating metformininduced tumor suppression. Several studies have now shown that
higher doses of metformin are required in mice to have antitumor
effects than those administered in clinical trials and this may be
a reflection of pharmacokinetic differences between rodents and
humans (86, 105, 106).
Attention is now also being paid to the impact of metformin
on other cellular components of the tumor microenvironment
(TME) beyond the cancer cells themselves as described in
Rivadeneira and Delgoffe (107). Metformin is capable of
decreasing the rate of tumor cell oxygen consumption and thus
is able to reduce hypoxia levels within the tumor. The reduction
of hypoxia can enhance the activity of agents aimed at stimulating
anti-tumor T-cells (108). Further effects of metformin on the
immune microenvironment are hypothesized to be mediated
through tumor-associated macrophage reprogramming from an
M2 to M1-like phenotype (109). A review on the effects of
metformin on other tumor cells is beyond the scope of this
work. In sum, the pre-clinical data provide sufficient evidence
for continued evaluation of metformin’s antineoplastic potential.
Nonetheless, they also highlight the likely complex interaction
between tumor- and patient-specific factors dictating the efficacy
of metformin as an anticancer treatment and underscore the need
for ongoing human studies.

they reported that metformin treatment increased FOXO1
protein levels, decreased inhibitory FOXO1 phosphorylation,
and increased FOXO1 nuclear accumulation in an AMPKdependent manner, resulting in inhibition of endometrial cancer
cell proliferation. Conversely, knockdown of FOXO1 expression
using siRNA partially attenuates the antiproliferative effect of
metformin on endometrial cancer cells. Metformin treatment
inhibited growth of tumors in a xenograft mouse model, and
tumor staining also showed increased phospho-AMPK and
nuclear localization of FOXO1 as well as decreased staining
of the proliferative marker Ki-67 (72). Decreased FOXO1
expression during metformin treatment has been reported by
others as well (68).
Metformin treatment has also been shown to inhibit
epithelial-to-mesenchymal transition (EMT) in endometrial
cancer cell lines. Metformin increases epithelial markers such
as E-cadherin and pan-keratin in endometrial cancer cells in
vitro (76, 100) and decreases mesenchymal markers (e.g., Ncadherin, fibronectin, vimentin) (76, 100) and transcriptional
drivers of EMT (e.g., Twist-1, snail-1, zinc finger E-box-binding
homeobox-1 [ZEB-1]) (100). In cultured cells, metformin was
able to attenuate the molecular and morphologic changes
induced by EMT-inducing stimuli such as 17β-estradiol and
transforming-growth factor-β (TGF-β) (76). Correspondingly,
histologic staining for E-cadherin was significantly higher in
endometrial carcinomas taken from patients with a history of
metformin use (100).
Metformin has demonstrated the ability to synergize with
other endometrial cancer therapies in vitro, leading to enhanced
apoptosis of cultured endometrial cell lines in the presence of
paclitaxel (74, 101), cisplatin (101, 102), or progestin (89). For
the latter two, this effect is dependent on downregulation of
glycoxylase I (GloI), a mediator of chemotherapy resistance (89,
101). Metformin treatment was also able to increase expression
of the progesterone receptor in endometrial cancer cells (88)
and sensitize progestin-resistant endometrial carcinoma cells
to medroxyprogesterone-induced apoptosis (89). Conversely,
metformin alters expression of the estrogen receptor (ER) in
endometrial cancer cells, decreasing the ERα isoform while
increasing expression of ERβ, with overall inhibition of estradiolinduced proliferation (90). In endometrial cancer patients with
type 2 diabetes, metformin leads to decreased expression of the
estrogen receptor in tumor tissue compared to insulin treatment
(103).
Possible mutation-specific effects of metformin have also been
explored in preclinical in vivo models of endometrial cancer. Oral
metformin is capable of reducing in vitro cell proliferation as
well as tumor size in xenograft models of multiple human and
mouse endometrial cancer cell lines. (67). This effect occurred
only in cell lines with activating K-Ras mutations but not wildtype K-Ras and could be partially attenuated by siRNA-based
inhibition of K-Ras expression. Moreover, metformin treatment
was shown to cause mislocalization of K-Ras to the cytoplasm in
a protein kinase C (PKC)-dependent manner. No association was
seen between metformin-responsiveness and PTEN mutations.
Another study utilized a primary endometrioid endometrial
carcinoma xenograft model using cells taken directly from
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METFORMIN IN PRESURGICAL AND
OTHER CLINICAL TRIALS IN
ENDOMETRIAL CANCER
The preponderance of preclinical data has prompted several early
phase clinical trials of metformin in human endometrial cancers
(Table 3). Many groups have utilized the pre-surgical window
approach, in which patients with a biopsy-based histologic
diagnosis of endometrial cancer receive metformin treatment
during the period prior to hysterectomy. Compared to baseline
levels or control patients, patients receiving metformin (between
850 and 2,250 mg daily) showed a post-treatment reduction
in markers of DNA replication (topoisomerase IIα) (112) and
cellular proliferation (Ki-67) (111, 114, 115, 119). No change in
Ki-67 staining was observed by Soliman and colleagues, though
notably the dose and duration of metformin exposure was the
lowest among these studies (117). Metformin treatment was
associated with histologic evidence for inhibition of key signaling
pathways including PI3K/Akt/mTOR (111, 112, 114, 116, 117,
119) and MAPK/ERK (112, 117). Tumor immunohistochemistry
in one trial also revealed decreased expression of estrogen
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Single arm

Single arm

Single arm

NonEffect of metformin on tumor biomarkers
during window from biopsy-proven
randomized
controlled trial diagnosis of AEH or EEC to surgical
resection

NonEffect of metformin on serum and tumor
randomized
biomarkers during window from
controlled trial biopsy-proven diagnosis of EC and
surgical resection in non-diabetic women

Single arm

Single arm

(112) (Japan)

(113) (China)

(114) (USA)

(115) (UK)

(116) (China)

(117) (USA)

(118) (Japan)

Metformin 850 mg daily from enrollment to
surgery (7–24 days, median 9.5 days)

Metformin 500 mg three times daily from
enrollment to surgery (3–4 weeks) vs. no
treatment

Metformin 850 mg twice daily from
enrollment to surgery (7–34 days, median
20 days) vs. no treatment

N/A

30

12 (2
AEH, 10
EEC)

N/A

NonEffect of metformin on tumor biomarkers
during window from biopsy-proven
randomized
controlled trial diagnosis of EC to surgical resection

Metformin 500 mg three times daily for 3–4 32
weeks

33

16 AEH,
13 EC

20

30

28 (0
AEH, 28
EEC)

20

5

N/A

Cyproterone acetate 2 mg daily, ethinyl
estradiol 35 µg daily, and metformin
1,000 mg daily for 6 months
Metformin 850 mg daily from enrollment to
surgery (7–28 days, mean 14.65 days)

31

10
(banked
tissues)

• EC patients had higher tumor Ki-67, PI3K, phospho-Akt, phosphoS6K1, and phospho-4E-BP1 at baseline than non-EC patients
• Metformin decreased tumor Ki-67, PI3K, phospho-Akt,
phospho-S6K1, and phospho-4E-BP1 in EC patients

• Metformin maintenance associated with 3-year recurrence-free
survival of 89%, compared to expected baseline of 52%
recurrence-free survival at 2 years

• Metformin decreased serum IGF-1, omentin, insulin, C-peptide, and
leptin
• Metformin decreased tumor phospho-Akt, phospho-rpS6,
phospho-ERK1/2 but did not change levels of Ki-67, phospho-ACC
or caspase-3

• EC patients had higher serum IGF-1, lower tumor phospho-AMPK,
and higher tumor phospho-mTOR at baseline than non-EC patients
• Metformin led to lower serum IGF-1, higher tumor phospho-AMPK
and lower tumor phospho-mTOR in EC patients

• Metformin decreased tumor Ki-67 and phospho-4E-BP1 but did not
change levels of phospho-Akt, phospho-ACC, phospho-rpS6, ER,
PR, or caspase-3

• Metformin decreased tumor Ki-67, phospho-AMPK, phospho-Akt,
phospho-rpS6, phospho-4E-BP-1 and ER but did not change PR
level
• Responders had increased serum free fatty acids and tumor staining
for markers of fatty acid oxidation and glycogen synthesis

• Estrogen/progesterone treatment combined with metformin led to
reversion to normal endometrial epithelium in all patients

• Metformin reduced tumor topoisomerase IIα, Ki-67, phospho-rpS6,
and phospho-ERK1/2 and increased tumor phospho-AMPK
• Metformin decreased serum insulin, glucose, and IGF-1
• metformin decreased ability of sera to stimulate DNA synthesis in
cultured cells

• Metformin reduced plasma insulin, IGF-1 and IGFBP-7 and decreased
tumor Ki-67 and phospho-rpS6.
• Metformin treatment led to non-significant increase in plasma
IGFBP-1

11 (8
EEC, 3
NEEC)

Metformin starting dose 750 mg daily,
increased weekly as tolerated to
1,500–2,250 mg daily (divided) from
enrollment to surgery (4–6 weeks)

10
(banked
tissues)

Efficacy of metformin in preventing
Metformin starting dose 750 mg daily,
N/A
recurrence after progestin therapy for AEH increased weekly as tolerated to 2,250 mg
or early stage EC (stage Ia)
daily (divided, concurrent with
medroxyprogesterone acetate-based
protocol for 24–36 weeks, continued
alone in complete responders until
conception or recurrence)

Effect of metformin on serum and tumor
biomarkers during window from
biopsy-proven diagnosis of EC to surgical
resection

Effect of metformin on tumor biomarkers
during window from biopsy-proven EEC
diagnosis to surgical resection in obese
women

Effect of metformin plus
estrogen/progesterone combination on
early stage EC (Ia) in women with PCOS

Effect of metformin on serum and tumor
biomarkers during window from
biopsy-proven EC diagnosis to surgical
resection in non-diabetic patients

Metformin 500 mg three times daily from
enrollment to surgery (21–50 days, mean
36.6 days, median 38 days)

• Metformin induced endometrial atrophy in 95.5% (21/22) of patients
(including 2 with low grade EEC) compared to 61.9% (13/21)
receiving megestrol

Results

22

No MFM MFM

Metformin 500 mg twice daily or megestrol 21
40 mg daily for 3 months

Treatment

MFM, metformin; EC, endometrial cancer; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial cancer; IGF-1, insulin-like growth factor-1; IGFBP-1/7, insulin-like growth factor binding protein-1/7; rpS6,
ribosomal protein S6; ERK1/2, extracellular signal-regulated kinase-1/2; AMPK, AMP-activated kinase; PCOS, polycystic ovary syndrome; Akt, protein kinase B; 4E-BP1, eukaryotic initiation factor 4E-binding protein-1; ER, estrogen
receptor; PR, progesterone receptor; AEH, atypical endometrial hyperplasia; ACC, acetyl-CoA carboxylase; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; S6K1, S6 kinase 1.

(119) (China)

Single arm

(111)
(Canada)

Effect of metformin on serum and tumor
biomarkers during window from
biopsy-proven EC diagnosis to resection
in non-diabetic patients

Endometrial histology after metformin vs.
Non-blinded
progesterone treatment for dysfunctional
randomized
controlled trial uterine bleeding

(110) (Iran)

Assessment

Design

References

TABLE 3 | Clinical trials of metformin in endometrial cancer.
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THE METABOLIC MICROENVIRONMENT
AS A THERAPEUTIC TARGET IN
ENDOMETRIAL CANCER

receptor after metformin treatment (114). Plasma measures
of a hyperinsulinemic state, including insulin, IGF-1, glucose,
and leptin were significantly reduced post-metformin (111, 112,
116, 117). Furthermore, serum from metformin-treated patients
showed decreased ability to stimulate DNA synthesis in cultured
endometrial cancer cells (112), suggesting that systemic effects of
metformin also play a role in its antiproliferative activity.
In terms of clinical outcomes, a randomized study by Tabrizi
examined the ability of metformin to reverse endometrial
hyperplasia or disordered proliferative endometrium in patients
with abnormal uterine bleeding compared to megestrol.
Metformin was able to induce endometrial atrophy/restore
endometrial histology in 95.5% of patients compared to 61.9%
in the megestrol group. Significantly, this study included two
patients with low grade endometrial carcinomas (stage Ia) who
received metformin. After 3 months of treatment, repeat biopsy
showed conversion to atrophic endometrium (110). A study
of 5 PCOS patients with early stage endometrial carcinoma
showed that co-treatment with the oral contraceptive Diane-35
(cyproterone and ethinyl estradiol) and metformin for 6 months
led to reversion to normal epithelia on repeat biopsy in all
patients (113). This included three patients who had previously
been on megestrol treatment for 3 months with documented
progesterone resistance. Mitsuhashi also used a combination
approach of metformin with medroxyprogesterone to induce
remission in patients with atypical endometrial hyperplasia
(AEH) or early stage endometrial cancer, and further studied the
use of maintenance metformin to prevent relapse. Metformin
treatment led to a relapse-free survival of 89% at 3 years,
which was higher than their projected baseline of 52% (118).
These studies were also notable for their stated goal of fertility
preservation, an important consideration for some endometrial
cancer patients.
Larger trials are underway, including a phase 3 trial of
metformin monotherapy as chemoprevention for endometrial
cancer compared to placebo and lifestyle interventions in
non-diabetic obese women (NCT01697566) and a phase
2/3 trial by the Gynecologic Oncology Group for advanced
(stage III, IVA, IVB) or recurrent endometrial cancer
that will compare the addition of metformin vs. placebo
to combination paclitaxel/carboplatin as first-line therapy
(NCT02065687). Several phase 2 or earlier studies will utilize
metformin in combination with hormonal treatments such
as megestrol acetate (NCT01968317) or levonorgestrel (as
an intrauterine device) for early stage endometrial cancer
or complex atypical hyperplasia in young women with
the goal of fertility preservation or contraindications to
surgery (NCT02990728, NCT02035787, NCT01686126).
Also ongoing are a phase 2 study of metformin combined
with letrozole and everolimus for advanced or recurrent
endometrial cancer (NCT01797523) and a phase 1/2 study
of metformin plus metronomic cyclophosphamide and
olaparib for advanced or recurrent endometrial cancer
(NCT02755844). These efforts will give valuable insight
into the preventative and therapeutic value of metformin in
endometrial malignancy.
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The role of glucose metabolism in endometrial cancer is also
still being explored. Malignant tissues in general have been
known to have high levels of glycolytic metabolism, even
in the presence of oxygen, a phenomenon known as the
Warburg effect after its discoverer, Otto Warburg (120). One
theory was that cancer cells are less dependent on oxidative
phosphorylation, allowing them to survive in the often relatively
hypoxic tumor microenvironment. However, in recent years,
a more nuanced model has emerged for some tumor types,
known as the reverse Warburg theory (121). This is based
on the recognition of heterogeneity in tumor composition;
malignant tissues are composed of cancer cells surrounded by
diverse types of stromal cells and adipocytes, each of which
make contributions to the tumor microenvironment (122, 123).
Our research in breast and prostate cancer cell models among
others have demonstrated that glycolysis occurs not in the tumor
cells themselves, but in the surrounding stromal cells (124–
127). This relationship is thought to occur via oxidative stress
in the cancer associated stroma (CAS), driven by tumor cell
generation of reactive oxygen species and stromal cell loss of
caveolin-1 (CAV1), an inhibitor of nitric oxide production (124–
129). CAS cells undergo metabolic reprogramming associated
with mitophagy (selective degradation of mitochondria by
autophagy) and cell autophagy, and they generate high levels of
energy-rich metabolites (including lactate and ketones) through
glycolysis, which is then shuttled to cancer cells as substrates
for oxidative phosphorylation. We have reported that lactate
shuttling to tumor epithelial cells is dependent on transporters
of the monocarboxylate transporter (MCT) family, with MCT4
being important for lactate efflux from stromal cells and
MCT1 for lactate uptake in tumor epithelial cells in a breast
cancer cell co-culture system (130). Others have observed
similar lactate shuttling in prostate cancer and sarcoma models
and have reported that lactate upload promotes tumor cell
proliferation and angiogenesis (131, 132). Aside from lactate,
Sousa and colleagues have described a similar two-compartment
metabolic system in pancreatic ductal adenocarcinoma in which
stroma-associated pancreatic stellate cells are stimulated by
contact with pancreatic cancer cells to undergo autophagy and
secrete primarily alanine which fuels the tricarboxylic acid
(TCA) cycle and biosynthesis in the cancer cells themselves
(133).
In this model, metformin treatment may play an important
part in disrupting cancer cell metabolism via its direct inhibition
of mitochondrial respiration in the cancer cells. In agreement
with this, our previous results suggest that metformin treatment
of cultured breast cancer cells inhibits their ability to induce loss
of CAV1 (a marker of tumor-stromal metabolic coupling) in cocultured fibroblasts (126). We have also observed that a short
course of metformin was also able to increase stromal CAV1
expression in vivo in patients with head and neck squamous cell
carcinoma in a presurgical window of opportunity trial (106).
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CONCLUSIONS

The existence of such symbiotic metabolic reprogramming
has not yet been investigated closely in endometrial cancer, but
supportive evidence comes from a study by Latif et al. that
showed differential histologic localization for MCT1 (tumor)
vs. MCT4 (stroma) for some though not all endometrial
cancer samples analyzed (134). High MCT1 expression was
also a poor prognostic indicator for recurrence-free, cancerfree, and overall survival in the same study. Moreover,
Zhao studied endometrial stromal-epithelial cell interactions
in a non-cancer primary cell culture model and showed
that epithelial cell proliferation and migration was enhanced
when cultured with conditioned media from CAV1 depleted
stromal cells (135). A phase 2 study currently underway
at our institution utilizes a combination of metformin and
doxycycline for the treatment of breast and uterine cancers,
with outcomes including the measurement of biomarkers
of tumor-stromal metabolic compartmentalization, such as
stromal CAV1 and MCT4 and tumor MCT1 (NCT02874430).
This will provide new insight into the effects of metformin
treatment on the metabolic microenvironment in endometrial
cancer.
The Reverse Warburg framework also opens up the
possibility of multi-targeted therapies that simultaneously
act on aberrant glucose metabolism in both cancer and
stromal cells, such as metformin combined with inhibitors
of glycolysis, autophagy, or transport of lactate and other
energetic substrates. Combined metformin and glycolytic
inhibitors have been utilized in xenograft models of breast
cancer, gastric cancer, and glioblastoma with synergistic
inhibition of tumor growth or prolongation of survival occurring
at doses where each agent is ineffective alone (136, 137).
Such approaches would exploit the vulnerabilities of tumorstroma metabolic reprogramming that typically allow for
cancer cell survival under a variety of energetic conditions.
Overall, the metabolic microenvironment of endometrial
cancer represents a promising therapeutic target, one which
metformin and other biguanides may be uniquely poised to act
upon.

Endometrial cancer is a disease with few effective treatments
for advanced and metastatic disease. In addition, the need for
fertility-sparing options for patients with early stage disease
means there is a need for more primary or adjunctive
treatment approaches. A large body of evidence links endometrial
cancer incidence to metabolic conditions such as obesity and
hyperglycemic states. Increasing rates of the latter has been
mirrored by a rise in the former, particularly in developing
countries, highlighting the need for a better understanding
of the contribution of the metabolic microenvironment to
endometrial cancer tumorigenesis. There is substantial evidence
that the mechanisms of nutrient utilization and synthesis are
significantly dysregulated in malignancy on both an intracellular
and intercellular level. Models such as the reverse Warburg effect
especially emphasize the importance of considering the interplay
between cancer epithelial cells and their surrounding stroma.
Dysregulation of metabolic pathways may represent adaptations
that facilitate survival and proliferation in some scenarios (e.g.,
the idea of the parasitic cancer cell), but can also become
liabilities for cancer cells particularly in times of nutrient or
energy deprivation. Drugs such as metformin may be uniquely
poised to exploit these defects, possibly in conjunction with other
therapies that target glucose utilization. Indeed, preclinical and
early clinical studies have shown promise for metformin as an
adjunctive treatment for endometrial cancer, with effects on both
cancer-specific as well as patient-specific metrics. Further study
is needed to elucidate the role of metformin as a therapy for
endometrial cancer, and several clinical trials are underway that
will greatly expand our understanding of its potential benefits.
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